Investing Profile

Perry Nisen

InvestorVC
Executive Partner/Advisor at Sofinnova Investments
Photo of Perry Nisen, Advisor at Sofinnova Investments

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Stanford University Network
925 CONNECTIONS
GSK Network
32 CONNECTIONS
GSK Network
32 CONNECTIONS
GSK Network
32 CONNECTIONS
GSK Network
32 CONNECTIONS
cb
$100K - $5.0M
$1.5M
2
CompanyStageDateRound SizeTotal Raised
XyloCor Therapeutics
Series AMar 2021$23M
Series ADec 2018$17M
$40M
Division VP Cancer Research AbbottPresent
Division VP Global Oncology Development AbbottPresent
SVP Clinical Pharmacology and Discovery Medicine GSKPresent
SVP Cancer Research GSKPresent
Senior Vice President and Therapeutic Area Head, Oncology Research and Development GSKPresent
Interim Chief Medical Officer GSKPresent
SVP Science and Innovation GSKPresent
Independent Director, Chair of Science and Technology Teva PharmaceuticalsPresent
Chief Executive Officer, Donald Bren Chief Executive Chair Sanford Burnham PrebysPresent
Executive Partner/Advisor Sofinnova InvestmentsPresent
Chief Executive Officer Quanta TherapeuticsPresent
The University of Texas Southwestern Medical Center at Dallas Bachelor's degree Medical Microbiology
Stanford University Bachelor's degree Medical Microbiology
Albert Einstein College of Medicine MD, PhD Medicine
Albert Einstein College of Medicine of Yeshiva University MD, PhD Medicine
Albert Einstein College of Medicine MD PhD, Medicine